NEW YORK (GenomeWeb News) – German molecular diagnostics company Epigenomics reported today that its first-quarter revenues increased 46 percent year over year.

For the three months ended March 31, total revenues were €355,000 ($468,000), up from €243,000 in the first quarter a year ago.

Its product sales increased to €163,000 from €125,000 a year ago, while R&D service income shot up to €126,000 from €4,000. Licensing revenues were down to €66,000 from €114,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.